Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30698644

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Ann Oncol
Publication date
2019 Apr 1
First author
Ghesquieres H

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Ann Oncol. 2019 Aug 1;30(8):1397-1398. doi: 10.1093/annonc/mdz142.
    note
    Source null
    related pmid
    31046114
    relationship
    Comment in
  2. citation
    Ann Oncol. 2019 Aug 1;30(8):1398-1399. doi: 10.1093/annonc/mdz161.
    note
    Source null
    related pmid
    31095293
    relationship
    Comment in

Authors and identifiers

  1. name
    Ghesquieres H
    type
    Author
  2. name
    Chevrier M
    type
    Author
  3. name
    Laadhari M
    type
    Author
  4. name
    Chinot O
    type
    Author
  5. name
    Choquet S
    type
    Author
  6. name
    Moluçon-Chabrot C
    type
    Author
  7. name
    Beauchesne P
    type
    Author
  8. name
    Gressin R
    type
    Author
  9. name
    Morschhauser F
    type
    Author
  10. name
    Schmitt A
    type
    Author
  11. name
    Gyan E
    type
    Author
  12. name
    Hoang-Xuan K
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Ghesquieres H
    type
    Author
  2. name
    Chevrier M
    type
    Author
  3. name
    Laadhari M
    type
    Author
  4. name
    Chinot O
    type
    Author
  5. name
    Choquet S
    type
    Author
  6. name
    Moluçon-Chabrot C
    type
    Author
  7. name
    Beauchesne P
    type
    Author
  8. name
    Gressin R
    type
    Author
  9. name
    Morschhauser F
    type
    Author
  10. name
    Schmitt A
    type
    Author
  11. name
    Gyan E
    type
    Author
  12. name
    Hoang-Xuan K
    type
    Author
bibliography ids
  1. nci-bib-734bab8937b4b13e4b5378d8
book metadata
content sha256
acf4e3ca736f972868cb2e36eaafb2b3878f9bac2922abc2f34b2c1f5822e8dc
document type
citation
dois
  1. 10.1093/annonc/mdz032
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:30698644
immutable id
pubmed:30698644@acf4e3ca736f972868cb2e36eaafb2b3878f9bac2922abc2f34b2c1f5822e8dc
journal
abbreviation
Ann Oncol
issn electronic
1569-8041
issn print
0923-7534
issue
4
name
Annals of oncology : official journal of the European Society for Medical Oncology
nlm unique id
9007735
pages
621-628
volume
30
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Ann Oncol. 2019 Aug 1;30(8):1397-1398. doi: 10.1093/annonc/mdz142.
    note
    Source null
    related pmid
    31046114
    relationship
    Comment in
  2. citation
    Ann Oncol. 2019 Aug 1;30(8):1398-1399. doi: 10.1093/annonc/mdz161.
    note
    Source null
    related pmid
    31095293
    relationship
    Comment in
outcomes validated
false
pmid
30698644
provenance
batch id
e808962322f3afebc564
provider
NCBI PubMed ESummary
record sha256
59cab7508838c58c116384d899ca26f07c7f3b582427752c7730c3c05a40e08d
response sha256
3d610336ca8dae92b82cdb6b3ee6cab382eb509e0349b0c68c261b042b036561
retrieved at
2026-09-09T23:47:41.002093+00:00
publication date
display
2019 Apr 1
precision
day
year
2019
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30698644/
title
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.

Preserved source evidence · Not medical advice